ClinicalTrials.gg
WithdrawnNCT01120431INFUSE-TMUpdated May 8, 2017

Efficacy and Time and Resources for Hylenex-facilitated SC Rehydration Versus ORT for Dehydrated Children in the Emergency Department (ED)

A Phase 4 interventional study of Oral rehydration fluid and Isotonic hydration fluid and recombinant human hyaluronidase in Dehydration, sponsored by Baxter Healthcare Corporation. Withdrawn. Open to participants aged 2 Months to 2 Years. Per ClinicalTrials.gov, last updated 2017-05-08.

Sponsored by Baxter Healthcare Corporation · Phase 4, Interventional, and Treatment

Why this study was withdrawn
Strategic business decision (not related to safety or efficacy concerns)

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
2 Months to 2 Years
Sex
All
01

Study summary

The purpose is to evaluate the safety and efficacy as well as the time and resources needed in the ED setting to achieve rehydration in young pediatric subjects with mild to moderate dehydration using hylenex-facilitated SC rehydration versus oral rehydration therapy.

02

Conditions studied

  • Dehydration

Browse trials for

Keywords

  • dehydration
  • fluid therapy
  • hyaluronoglucosaminidase
  • hyaluronidase
  • hypodermoclysis
  • clysis
  • subcutaneous hydration
  • subcutaneous rehydration
  • hyaluronan
  • rHuPH20
  • pediatric
  • ORT
03

In context

Dehydration

201 studies on the registry are indexed under Dehydration; 28 are open to participants now.

Browse Dehydration studies →

Lead sponsor

Baxter Healthcare Corporation is the lead sponsor of 80 studies on the registry; 1 is open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 3 (30%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
2 Months to 2 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female and aged 2 months to 2 years
  • Presenting to ED with mild or moderate dehydration
  • Candidate for both parenteral and oral rehydration therapies
  • Healthy, except for underlying etiology for dehydration
  • Naive to ORT or having received attempted ORT at home for current occurrence of dehydration.
  • Pre-dehydration body weight greater than 5th percentile for age

Exclusion criteria

Exclusion Criteria:

  • Severe dehydration
  • Shock or a life-threatening situation
  • Any condition precluding SC infusion or infusion site evaluation in all possible anatomical locations (upper back, anterior thighs, abdomen, other potential areas) for SC infusion
  • Medical reason or condition precluding administration of ORT
  • Indwelling IV catheter (except one intended only for laboratory sample collection) or anticipated need for IV therapy during the study
  • Anticipated need for hospitalization(other than for rehydration)
  • Known to hyaluronidase or any other ingredient in the formulation of hylenex recombinant
  • Known hyponatremia, hypernatremia or hypokalemia
  • Medical condition likely to interfere with ability to fully complete protocol-specified interventions and assessments, or likely to prolong need for medical attention beyond that required for rehydration
  • Participation in an drug or device study within 30 days before participation in this study
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Active comparator
    Oral rehydration therapy

    Other: Oral rehydration fluid

  • Experimental
    hylenex-facilitated SC hydration

    Drug: Isotonic hydration fluid and recombinant human hyaluronidase

Interventions

  • OtherOral rehydration fluid

    Oral electrolyte solution or other clinically acceptable oral rehydration fluid, 5 to 10 mL of offered with encouragement every 5 to 10 minutes

    Also known as: oral rehydration salts

  • DrugIsotonic hydration fluid and recombinant human hyaluronidase

    Drug page: Hyaluronidase (human recombinant)

    Single subcutaneous dose of 150 U recombinant human hyaluronidase, followed by infusion pump-delivered subcutaneous isotonic hydration fluid

    Also known as: hyelenx, rHuPH20, Lactated Ringer's solution, normal saline solution, 0.9% sodium chloride solution

06

What researchers measure

Primary outcomes

  1. Total resource utilization in the ED

    Time frame: 2 to 8 hours

Secondary outcomes

  1. Rate of successful rehydration in the ED

    Clinical judgement of adequate hydration, and either: 1) stable or increased body weight or 2) urine production

    Time frame: 2 to 8 hours

  2. Time to ED discharge

    Time frame: 2 to 8 hours

  3. Amount of rehydration fluid administered

    Time frame: 2 to 8 hours

  4. Global satisfaction and ease-of-use assessments by healthcare provider(s) and parent/caregiver

    Time frame: 2 to 8 hours

  5. Occurrence of infusion site pain or other local reactions

    Time frame: 2 to 8 hours

  6. Occurrence of other adverse events

    Time frame: 7 days

  7. Vital signs

    Blood pressure, heart rate, respiratory rate, temperature

    Time frame: 2 to 8 hours

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for May 2010; primary completion for May 2010, 0 months later.

How these figures are worked out, and which studies are left out of them.

Registered
May 7, 2010
First posted
May 11, 2010
StartEst.
May 2010
Primary completionEst.
May 2010
CompletionEst.
May 2010
Last update
May 8, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 8, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01120431
Responsible party
Sponsor
First posted
May 11, 2010
Start date
May 2010 (estimated)
Primary completion
May 2010 (estimated)
Completion
May 2010 (estimated)
Last update
May 8, 2017

Study contacts

George Harb, MD, MPH
study director · Baxter Healthcare Corporation

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in May 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Hyaluronidase (human recombinant)

Start the discussion